CliffBio
biologic

Pombiliti

cipaglucosidase alfa-atga

Loss of exclusivitySeptember 2035projected — 12-year biologic exclusivity estimate
CompanyAmicus Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand namePombiliti
Active ingredientcipaglucosidase alfa-atga
Strength105MG
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2023
Marketing statusRx

More from Amicus Therapeutics

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.